Eli Lilly to invest $450 million more to expand diabetes drug plant capacity

Published by

(Reuters) – Eli Lilly and Co said on Tuesday it plans to invest an additional $450 million to expand its manufacturing capacity at the Research Triangle Park facility in North Carolina to support increased demand for its key diabetes drugs. The company has been struggling to meet high demand for the drugs Trulicity and Mounjaro, especially due to production of multiple dosage forms for each of them. The U.S. Food and Drug Administration last month added both the names to its list of drugs facing shortages. The company already had plans to double the production capacity this year for incretins,…

Read More

Leave a Reply